Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19.


Journal

Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460

Informations de publication

Date de publication:
06 2021
Historique:
revised: 24 11 2020
received: 23 10 2020
accepted: 28 12 2020
pubmed: 11 2 2021
medline: 22 5 2021
entrez: 10 2 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19), can present with a wide spectrum of severity. Elderly patients with cardiac, pulmonary and metabolic comorbidities are more likely to develop the severe manifestations of COVID-19, which are observed in less than 5% of the pediatric patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to induce an immune impairment and dysregulation, finally resulting in the massive release of inflammatory mediators, strongly contributing to the pulmonary and systemic manifestations in COVID-19. In children, the immune dysregulation following SARS-CoV-2 can also be responsible of a severe disease phenotype defined as multisystem inflammatory syndrome in children. As the immune system undergoes a complex process of maturation from birth to adult age, differences in the immune and inflammatory response could have a significant impact in determining the spectrum of severity of COVID-19. Indeed, children show a higher ability to respond to viral infections and a reduced baseline pro-inflammatory state compared with elderly patients. Age and comorbidities contribute to disease severity through immune-mediated mechanisms, since they are associated with a chronic increase of pro-inflammatory mediators, and cause an enhanced susceptibility to develop an immune dysregulation following SARS-CoV-2 infection. Also the expression of ACE2, the receptor of SARS-CoV-2, varies with age, and is linked to the immune and inflammatory response through a complex, and not completely elucidated, network. This paper reviews the peculiar immunopathogenic aspects of COVID-19, with a focus on the differences between adult and pediatric patients.

Identifiants

pubmed: 33566457
doi: 10.1002/iid3.404
pmc: PMC8014746
doi:

Substances chimiques

Receptors, Virus 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Comparative Study Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

331-339

Informations de copyright

© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Références

N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Life Sci. 2006 Apr 4;78(19):2166-71
pubmed: 16303146
N Engl J Med. 2020 Sep 10;383(11):1078-1080
pubmed: 32905684
Cell Host Microbe. 2020 Jun 10;27(6):870-878
pubmed: 32464097
Eur Respir J. 2020 May 14;55(5):
pubmed: 32269089
Pediatr Infect Dis J. 2020 Jun;39(6):469-477
pubmed: 32398569
J Immunol. 1993 Jan 15;150(2):543-9
pubmed: 8419487
Immun Inflamm Dis. 2021 Jun;9(2):331-339
pubmed: 33566457
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
J Virol. 2010 Sep;84(18):9318-25
pubmed: 20610717
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Eur J Pediatr. 2020 Jul;179(7):1029-1046
pubmed: 32424745
J Med Virol. 2020 Jul;92(7):747-754
pubmed: 32232980
Int J Infect Dis. 2020 Jul;96:710-714
pubmed: 32389849
J Virol. 2007 Aug;81(16):8692-706
pubmed: 17537853
Elife. 2020 Nov 09;9:
pubmed: 33164753
Eur Respir J. 2020 Aug 20;56(2):
pubmed: 32675207
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
Immun Ageing. 2009 Jul 22;6:10
pubmed: 19624841
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Inflamm Res. 2020 Sep;69(9):825-839
pubmed: 32529477
Nat Rev Immunol. 2020 Aug;20(8):453-454
pubmed: 32546853
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Eur J Pediatr. 2020 Aug;179(8):1315-1323
pubmed: 32495147
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Curr Treatm Opt Rheumatol. 2017 Mar;3(1):33-48
pubmed: 28944163
Nat Rev Immunol. 2014 Jan;14(1):24-35
pubmed: 24336101
Virus Genes. 2011 Feb;42(1):37-45
pubmed: 20976535
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Pharmacol Res. 2020 Jul;157:104833
pubmed: 32302706
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
J Korean Med Sci. 2016 Nov;31(11):1717-1725
pubmed: 27709848
Proc Nutr Soc. 2012 May;71(2):332-8
pubmed: 22429824
J Exp Med. 2015 Oct 19;212(11):1851-68
pubmed: 26392224
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Nat Rev Rheumatol. 2016 May;12(5):259-68
pubmed: 27009539
Trends Immunol. 2009 Jul;30(7):306-12
pubmed: 19540809
Front Immunol. 2019 Feb 27;10:318
pubmed: 30873171
World J Pediatr. 2020 Jun;16(3):251-259
pubmed: 32193831
Transpl Int. 2020 Jul;33(7):824-825
pubmed: 32236983
Cell Physiol Biochem. 2015;37(2):759-67
pubmed: 26356266
Int J Mol Sci. 2020 Aug 12;21(16):
pubmed: 32806722
Pediatr Res. 2021 Mar;89(4):733-737
pubmed: 32555539
Allergy. 2020 Nov;75(11):2829-2845
pubmed: 32496587
Arthritis Rheum. 2012 May;64(5):1680-8
pubmed: 22108837
Ann Rheum Dis. 2016 Mar;75(3):481-9
pubmed: 26865703
Pediatr Pulmonol. 2020 Aug;55(8):1892-1899
pubmed: 32492251
Sci Rep. 2016 Jan 27;6:19840
pubmed: 26813885
Vaccine. 2018 Sep 18;36(39):5811-5818
pubmed: 30143274
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Best Pract Res Clin Rheumatol. 2014 Apr;28(2):277-92
pubmed: 24974063
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Int Immunol. 2012 Jun;24(6):347-56
pubmed: 22345276
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
Proc Am Thorac Soc. 2009 Dec 1;6(7):573-80
pubmed: 19934352
Environ Toxicol Pharmacol. 2020 Aug;78:103411
pubmed: 32422280
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Trends Immunol. 2009 Jul;30(7):313-8
pubmed: 19540810
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Geroscience. 2020 Apr;42(2):505-514
pubmed: 32274617
Immun Ageing. 2019 Sep 11;16:24
pubmed: 31528179
J Autoimmun. 2020 Aug;112:102463
pubmed: 32303424
J Med Virol. 2021 Jan;93(1):257-261
pubmed: 32603481
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Eur Cytokine Netw. 2018 Sep 1;29(3):83-94
pubmed: 30547890
Mech Ageing Dev. 2006 Mar;127(3):274-81
pubmed: 16352331
Front Oncol. 2020 Jan 31;9:1529
pubmed: 32076597
Cell Stem Cell. 2020 May 7;26(5):657-674.e8
pubmed: 32169166
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342
pubmed: 32202240
Children (Basel). 2020 Jul 01;7(7):
pubmed: 32630212
J Pathol. 2006 Nov;210(3):288-97
pubmed: 17031779

Auteurs

Giorgio Costagliola (G)

Division of Pediatrics, Department of Clinical and Experimental Medicine, Section of Rheumatology and Clinical Immunology, University of Pisa, Pisa, Italy.

Erika Spada (E)

Division of Pediatrics, Department of Clinical and Experimental Medicine, Section of Rheumatology and Clinical Immunology, University of Pisa, Pisa, Italy.

Rita Consolini (R)

Division of Pediatrics, Department of Clinical and Experimental Medicine, Section of Rheumatology and Clinical Immunology, University of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH